0001415889-22-011708.txt : 20221122 0001415889-22-011708.hdr.sgml : 20221122 20221122200011 ACCESSION NUMBER: 0001415889-22-011708 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221118 FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eldridge George A CENTRAL INDEX KEY: 0001413006 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 221411989 MAIL ADDRESS: STREET 1: C/O TARGANTA THERAPEUTICS CORPORATION STREET 2: 222 THIRD STREET SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-11222022_081101.xml X0306 4 2022-11-18 0001798749 Aerovate Therapeutics, Inc. AVTE 0001413006 Eldridge George A C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SEE REMARKS Common Stock 2022-11-18 4 M 0 861 2.14 A 2821 D Common Stock 2022-11-18 4 S 0 780 19.4541 D 2041 D Common Stock 2022-11-18 4 S 0 81 20.1335 D 1960 D Common Stock 2022-11-21 4 M 0 2 2.14 A 1962 D Common Stock 2022-11-21 4 S 0 2 19 D 1960 D Common Stock 2022-11-22 4 M 0 174 2.14 A 2134 D Common Stock 2022-11-22 4 S 0 174 19.0121 D 1960 D Stock Option (Right to Buy) 2.14 2022-11-18 4 M 0 861 0 D 2031-04-01 Common Stock 861 97815 D Stock Option (Right to Buy) 2.14 2022-11-21 4 M 0 2 0 D 2031-04-01 Common Stock 2 97813 D Stock Option (Right to Buy) 2.14 2022-11-22 4 M 0 174 0 D 2031-04-01 Common Stock 174 97639 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.06 to $20.045, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.095 to $20.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.03, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Officer Title: Chief Financial Officer and Treasurer /s/ George A. Eldridge 2022-11-22